Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 1
2021 1
2022 2
2023 2
2024 2
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20DL, 5BAuthor
Page 1
Association Between Myocardial Infarction and Quality of Life in the ISCHEMIA Trial.
Gaudino M, Stone GW, Heise RS, Caldonazo T, Kim J, Harik L, Sandner S, Biondi-Zoccai G, Masterson-Creber R, Alexander JH, Bhatt DL, Puskas J, Devereaux PJ, Spertus J, Redfors B. Gaudino M, et al. JACC Cardiovasc Interv. 2025 May 26;18(10):1263-1272. doi: 10.1016/j.jcin.2025.02.011. Epub 2025 Apr 23. JACC Cardiovasc Interv. 2025. PMID: 40272347 Free article. Clinical Trial.
European Quality of Life-5 dimensions visual analog scale (EQ-5D VAS) (generic) and Seattle Angina Questionnaire (SAQ-7) summary score (disease-specific) were used. ...SMI was associated with significant decreases in both early (adjusted difference -5.7; 95% CI: -7.3 to -4 …
European Quality of Life-5 dimensions visual analog scale (EQ-5D VAS) (generic) and Seattle Angina Questionnaire (SAQ-7) summary scor …
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Olasupo OO, Noronha N, Lowe MS, Ansel D, Bhatt M, Matino D. Olasupo OO, et al. Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2. Cochrane Database Syst Rev. 2024. Update in: Cochrane Database Syst Rev. 2026 Mar 24;3:CD014544. doi: 10.1002/14651858.CD014544.pub3. PMID: 38411279 Free PMC article. Updated.
Emicizumab 1.5 mg/kg/week did not improve Haem-A-QoL physical and total health scores, EQ-5D-5L VAS, or utility index scores (low-certainty evidence) when compared with on-demand therapy at 25 weeks. Emicizumab 3.0 mg/kg bi-weekly may improve HRQoL measured by the Haem-A-Q …
Emicizumab 1.5 mg/kg/week did not improve Haem-A-QoL physical and total health scores, EQ-5D-5L VAS, or utility index scores (low-cer …
Health utilities and costs for neuromyelitis optica spectrum disorder.
Hughes DA, Bourke S, Jones A, Bhatt R, Huda S, Mutch K, Jacob A. Hughes DA, et al. Orphanet J Rare Dis. 2022 Apr 7;17(1):159. doi: 10.1186/s13023-022-02310-z. Orphanet J Rare Dis. 2022. PMID: 35392962 Free PMC article.
METHODS: Patients with NMOSD and their carers, recruited via a regional specialist treatment centre, completed a postal questionnaire that included a resource use measure, the EuroQoL (EQ)-5D-5L, EQ-5D-VAS, Vision and Quality of Life Index (VisQoL), Carer Experience …
METHODS: Patients with NMOSD and their carers, recruited via a regional specialist treatment centre, completed a postal questionnaire that i …
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
Bhatt AS, Vaduganathan M, Claggett BL, Fonarow GC, Packer M, Pfeffer MA, Shah SJ, Shen X, Cristino J, McMurray JJV, Solomon SD, Gaziano TA. Bhatt AS, et al. JAMA Cardiol. 2023 Nov 1;8(11):1041-1048. doi: 10.1001/jamacardio.2023.3216. JAMA Cardiol. 2023. PMID: 37755814 Free PMC article.
Quality-of-life differences were estimated from EuroQol-5D scores. Hospitalization and medication costs were obtained from published national sources; the wholesale acquisition cost of sacubitril-valsartan was $7092 per year. ...
Quality-of-life differences were estimated from EuroQol-5D scores. Hospitalization and medication costs were obtained from published …
Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease.
Smolderen KG, Mena-Hurtado C, Eikelboom JW, Bosch J, Xie F, Ramasundarahettige C, Bhatt DL, Anand SS. Smolderen KG, et al. Eur J Prev Cardiol. 2023 May 9;30(7):535-545. doi: 10.1093/eurjpc/zwac282. Eur J Prev Cardiol. 2023. PMID: 36444513 Free article.
METHODS AND RESULTS: Stable CAD and PAD patients from the international, multi-centre COMPASS trial completed the visual analogue scale (VAS) of the EQ-5D-3L to assess overall health status, and the Digit Symbol Substitution test (DSST) to assess cognitive function. ...Pop …
METHODS AND RESULTS: Stable CAD and PAD patients from the international, multi-centre COMPASS trial completed the visual analogue scale (VAS …
Transcatheter valve-in-valve versus redo-surgical valve replacement for mitral bioprosthetic valve dysfunction: rationale and design of the SURVIV randomised trial.
Siqueira DA, Abizaid AAC, Ramos AA, Issa M, Cervone AC, Bezerra CG, de Araripe Falcão BA, Cortes LA, de Freitas C Guimarães L, K São Thiago LE, Rezende M, Delamain TR, Togna DD, Assef JE, Vilela AA, Paladino AT, Pinto IM, Franchini K, Bhatt DL, Feres F. Siqueira DA, et al. EuroIntervention. 2026 Mar 16;22(6):e358-e366. doi: 10.4244/EIJ-D-25-01090. EuroIntervention. 2026. PMID: 41834775 Free article. Clinical Trial.
Key secondary endpoints are major complications (cardiovascular death, disabling stroke, life-threatening or major bleeding, acute kidney injury stage 2 or 3, and major vascular complications) at 30 days, according to Mitral Valve Academic Research Consortium criteria; rehospital …
Key secondary endpoints are major complications (cardiovascular death, disabling stroke, life-threatening or major bleeding, acute kidney in …
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Olasupo OO, Noronha N, Lowe MS, Ansel D, Bhatt M, Matino D. Olasupo OO, et al. Cochrane Database Syst Rev. 2026 Mar 24;3(3):CD014544. doi: 10.1002/14651858.CD014544.pub3. Cochrane Database Syst Rev. 2026. PMID: 41873813
Emicizumab 1.5 mg/kg/week did not improve Haem-A-QoL physical and total health scores, EQ-5D-5L VAS, or utility index scores (low-certainty evidence) when compared with on-demand therapy at 25 weeks. Emicizumab 3.0 mg/kg bi-weekly may improve HRQoL measured by the Haem-A-Q …
Emicizumab 1.5 mg/kg/week did not improve Haem-A-QoL physical and total health scores, EQ-5D-5L VAS, or utility index scores (low-cer …
Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.
Xie F, Yan J, Eikelboom J, Anand S, Muehlhofer E, Pullenayegum E, Wang Y, Avezum A, Bhatt DL, Yusuf S, Bosch J. Xie F, et al. Eur Heart J Open. 2024 Sep 27;4(5):oeae083. doi: 10.1093/ehjopen/oeae083. eCollection 2024 Sep. Eur Heart J Open. 2024. PMID: 39439530 Free PMC article.
METHODS AND RESULTS: Health-related quality of life assessed using the EQ-5D-3L. The treatment effects on health utility and EQ visual analogue scale (EQ VAS) scores were compared between rivaroxaban plus aspirin and aspirin alone in terms of adjusted mean difference in ch …
METHODS AND RESULTS: Health-related quality of life assessed using the EQ-5D-3L. The treatment effects on health utility and EQ visua …
Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients.
Gupta T, Kolte D, Khera S, Goel K, Aronow WS, Cooper HA, Jain D, Rihal CS, Fonarow GC, Panza JA, Bhatt DL. Gupta T, et al. JAMA Cardiol. 2017 Mar 1;2(3):250-258. doi: 10.1001/jamacardio.2016.5131. JAMA Cardiol. 2017. PMID: 28097322
IMPORTANCE: Renal transplantation is associated with reduction in the risk for myocardial infarction (MI) in patients with chronic kidney disease requiring long-term dialysis (stage 5D CKD). Whether outcomes of MI differ among renal transplant recipients vs patients with s …
IMPORTANCE: Renal transplantation is associated with reduction in the risk for myocardial infarction (MI) in patients with chronic kidney di …
Patient-reported Outcomes After Metabolic Surgery Versus Medical Therapy for Diabetes: Insights From the STAMPEDE Randomized Trial.
Aminian A, Kashyap SR, Wolski KE, Brethauer SA, Kirwan JP, Nissen SE, Bhatt DL, Schauer PR. Aminian A, et al. Ann Surg. 2021 Sep 1;274(3):524-532. doi: 10.1097/SLA.0000000000005003. Ann Surg. 2021. PMID: 34132694 Free PMC article. Clinical Trial.
A subset of 104 patients participating in the STAMPEDE trial were administered two generic health-related quality of life (QoL) questionnaires (RAND-36 and EQ-5D-3L) and a diabetes-specific instrument at baseline, and then on an annual basis up to 5 years after randomizati …
A subset of 104 patients participating in the STAMPEDE trial were administered two generic health-related quality of life (QoL) questionnair …
13 results